Results: The prevalence of dyssynergic defaecation in patients investigated for chronic constipation is as many as 40%. Randomised controlled trials have demonstrated major symptom improvement in 70%-80% of patients undergoing biofeedback therapy for chronic constipation resistant to standard medical therapy and have determined it to be superior to polyethylene glycol laxatives, diazepam or sham therapy. Long-term studies have shown 55%-82% of patients maintain symptom improvement.
Functional constipation is a common clinical concern, representing approximately eight per cent of patient presentations in a primary care setting. 1 The Rome IV Criteria define functional constipation as at least two of six symptoms; need for straining, lumpy or hard stools, sensation of incomplete evacuation, sensation of anorectal obstruction and need for manual manoeuvres to facilitate defaecation more than one-fourth of defaecations or less than three defaecations per week for the last 3 months with symptom onset being at least 6 months prior to diagnosis (Table 1 ) and who do not already meet the criteria for constipation predominant irritable bowel syndrome. 2 
| Functional constipation subtypes
The true prevalence of subtypes of functional constipation is poorly defined as the studies in this area have generally been undertaken in tertiary or quaternary centers. As a result, the data are difficult to extrapolate to the general population as the majority of patients in the community are not investigated to a similar extent. Nevertheless, functional constipation subtypes are considered to include: (1) functional defaecatory disorders (diagnosed in 12%-24% of patients describing constipation), (2) slow transit constipation (5%-42%), (3) a combination of slow transit constipation and functional defaecatory disorder (2%-25%) and (4) constipation predominant irritable bowel syndrome (IBS), characterised by abdominal pain associated with defaecation, (20%) or normal transit constipation (20%-60%) depending on diagnostic definition and investigative modality. [3] [4] [5] The Rome IV criteria further divides functional defaecatory disorders into those due to paradoxical contraction or inadequate relaxation of the pelvic floor muscles during attempted defaecation (dyssynergic defaecation) and/or inadequate defaecatory propulsion. 6 The prevalence of dyssynergic defaecation in patients investigated for chronic constipation is thought to be as many as 40%, 7 however, evidence from the literature ranges from 13% to 81% depending on patient population and definition. 7 The epidemiological inaccuracy is in large part relating to historical controversy regarding the diagnostic definition of dyssynergic defaecation as well as lack of standardised investigative techniques.
| Biofeedback therapy
Biofeedback was first introduced as a treatment for dyssynergic defaecation in 1987. 8 Since then, biofeedback therapy has demonstrated clinical efficacy in uncontrolled trials and a small number of randomised controlled trials (RCT). 9 Biofeedback is based on "operant conditioning" techniques and uses instruments such as electromyography (EMG) sensors, balloons or manometry to guide the patient to increase intraabdominal pressure effectively and to coordinate relaxation of the pelvic floor and the anal sphincter musculature during defaecation. 10, 11 This review summarises the current evidence regarding (1) the pathophysiology of dyssynergic defaecation, (2) diagnosis of dyssynergic defaecation in chronic constipation and (3) efficacy of managing dyssynergic defaecation with biofeedback therapy.
| NORMAL DEFAECATION
Normal defaecation is complex. It requires the coordination of increased intraabdominal pressure in combination with concurrent pelvic floor muscle and anal sphincter relaxation, and intact rectal sensation and perception. 12 The three muscular components that influence continence are the pelvic floor muscles (levator ani), internal anal sphincter (IAS) and external anal sphincter (EAS) (Figure 1 ). 13 The levator ani is a broad muscular dome comprising of four muscles: puborectalis, iliococcygeus, ischiococcygeus and pubococcygeus which have voluntary and reflexive functions. 14 The latter three | 411 muscles function to provide physical support, acting as a dome shaped "diaphragm," for the pelvic viscera. 14 The puborectalis, in contrast, is a U-shaped muscle which forms a sling around the upper anal canal and interdigitates its muscular fibres with the EAS (located caudally) before attaching anteriorly on the pubis. 15 Puborectalis contraction pulls the anorectal junction anteriorly to form the anorectal angle. 16 This angulation of approximately 90°is maintained by tonic activity (postural reflex); creating a mechanical barrier which aids continence (Figure 2 ). 12 The internal and external sphincters also form a physical barrier to defaecation by maintaining a higher anal pressure than rectal pressure. 12 An increase in rectal distension mediates the initiation of rectal evacuation. 17, 18 If it is a socially appropriate time, a voluntary increase in intraabdominal pressure is coupled with puborectalis relaxation which widens the anorectal angle and straightens the passage of stool from the rectum to the anus ( Figure 2 ). This is followed by anal sphincter relaxation and stool evacuation. Inadequate defaecatory propulsion may also cause constipation due to an insufficient increase in intrarectal pressure despite relaxation of the anal sphincter. 21 The aetiology of dyssynergic defaecation is unclear. A prospective survey of 100 patients with dyssynergia suggested that symptoms began during childhood in 31%, after a physical event such as pregnancy, trauma or back injury in 29% and with no cause identified in 40% of patients. 10, 22 
| Balloon expulsion test
The balloon expulsion test is a simple, clinical procedure. A balloon tipped catheter is inserted in to the rectum and inflated with water to 50 mL. The patient is asked to evacuate the balloon while timed.
A normal test result is the expulsion of the balloon under one to two minutes, whereas, dyssynergia is suspected if the patient is unable to expel the balloon in under two minutes. 33 The balloon expulsion test has an 80%-90% specificity and sensitivity ranges from 33% to 94% for dyssynergia as defined by anorectal manometry 34 (which itself remains a controversial diagnostic tool given its possible high false positive rate. 35 ) There is a modest concordance between balloon expulsion test performed in the left lateral position or seated position. 36 However, a recent study concluded that balloon expulsion alone does not sufficiently predict response to biofeedback and recommended that additional modalities were needed to confirm the diagnosis. 37 
| Anorectal manometry
Anorectal manometry indirectly assesses anorectal function by measuring recto-anal pressures and motor coordination. 31 It evaluates:
(1) anal sphincter function (2) recto-anal reflex activity and (3) changes in anal and rectal pressures during simulated defaecation. 38 Furthermore, the current configuration of catheters allows integrated measurement of rectal sensation, rectal compliance and performance of a balloon expulsion test. 38 The original studies, that established the role of anorectal manometry for predicting response to biofeedback, employed the use of low-resolution anorectal manometry. 39 Recent technical advancements in anorectal manometry allow high-definition assessment of anorectal function, however, a blinded multiobserver study in 170 participants by Grossi et al., demonstrated that nearly 90% of healthy volunteers have a pattern regarded as "abnormal" based on traditional low-resolution manometric criteria during anorectal manometry performed in the left lateral position with an empty rectum. 35 The high false positive rate for manometry may be due to a number of factors. Firstly, anorectal testing is best undertaken in private due to subject anxiety in the laboratory setting. 35 . 40 Manometric data from this study demonstrated lower intrarectal pressure, anal resting and residual pressures in the left lateral position due to positional effects on sphincter tone and the effect of weight from the intraabdominal viscera. 40 This will intuitively result in an underestimation of rectal propulsive pressure. In addition, as anorectal function has a significant voluntary component, effective instruction and verbal feedback has been demonstrated to effect the manometric diagnosis. 41 Therefore, the findings from high resolution anorectal manometry need to be interpreted in context with supporting modalities, as in isolation, it has limited application. 31, 35 More studies are needed to determine if alternative metrics for high resolution/definition manometry improve its sensitivity and specificity.
| Electromyography
Electromyography assesses the activity of the external anal sphincter by detecting paradoxical muscular contraction via recording the number of motor units firing at a certain time point. Surface EMG is most commonly utilised, with electrodes placed on the anal skin over the external anal sphincter. A sustained increase in surface EMG activity (>50% increase from baseline) on attempted defaecation is defined as inappropriate contraction. 20, 42 EMG has been shown to correlate with balloon expulsion in 82% of patients.
43,44
| Defaecating proctography
Defaecating proctography involves the insertion of barium paste into the rectum followed by videofluoroscopy at rest and during rectal evacuation. 10, 45, 46 Defaecating proctography is a cost-effective procedure which mimics normal defaecation. A lack of perineal descent and an evacuation time longer than 30 seconds has been shown to be highly predictive of dyssynergia, 47, 48 although a recent study suggested evacuation may still be normal if as little as 35% of the rectum is emptied in two and a half minutes. 49 Unfortunately, defaecating proctography can be difficult to access outside of tertiary centers, may be uncomfortable as it is undertaken in a semipublic setting and involves exposure to low-dose ionising radiation (average dose 4.9 mSv). 50 As a result, defaecating proctogram is often reserved as a second line investigation for those who have not responded to biofeedback or in those in which there is a high index of suspicion of structural abnormalities.
Following confirmation of dyssynergia on diagnostic testing using two modalities, further management using a behavioural therapy such as biofeedback therapy can be commenced.
6 | BIOFEEDBACK THE RAPY
| Definition of biofeedback therapy
Biofeedback is a behavioural therapy which incorporates exercise repetition and simulation of defaecation to correctly coordinate abdominal and pelvic floor muscle contraction. 10 It is a form of oper- 
| Mechanism of action
Dyssynergic defaecation is thought to be primarily an acquired condition, therefore, the aim of biofeedback is to relearn a normal pattern of defaecation. 52 The mechanism by which biofeedback improves constipation symptoms and bowel function remains incompletely understood. Studies suggest that biofeedback acts locally and improves constipation by removing the mechanical barrier (acute anorectal angle) caused by paradoxical pelvic floor contraction.
Appropriate relaxation of the pelvic floor muscles allow stool to be propelled forward more readily and may eliminate retrograde peristalsis caused by pelvic floor contraction during defaecation. 42, 54, 55 Biofeedback may also have a role in neuromodulation of the gut. 42 At least one study has shown that patients with a positive response
to biofeedback therapy, demonstrate enhanced gut microcirculation resulting in a decreased stool transit time suggesting potential modification of autonomic pathways. 42 
| Instrument modalities
Instruments used for biofeedback may include a manometry system, electromyography (EMG), rectal balloon, ultrasound (intrarectal, intravaginal, perineal), digital guidance or visual feedback techniques.
56,57
The solid state manometry system includes a probe with microtransducers connected to a display unit for interpretation of pressure activity and a balloon for simulated defaecation and sensory training. 52 EMG biofeedback systems commonly include a surface electrode attached to an anal probe or a sensor, placed on the surface of the external anal sphincter, connected to a display unit to provide real time visual and auditory feedback. 52 Balloon biofeedback may be undertaken with the patient in the left lateral position or seated on a commode. A catheter with a balloon attached is inserted 10 cm into the rectum. Fifty millilitres (mL) of water or air is injected into the balloon to provide sensory awareness, the patient is instructed to generate increased intraabdominal pressure using the diaphragm and abdominal muscles while simultaneously relaxing the pelvic floor and anal sphincter muscles to release the balloon without straining. The therapist holds the end of the balloon catheter to assess balloon movement (propulsion) and may apply gentle traction to the balloon catheter to assist initially. If the patient is unable to evacuate a 50 mL balloon then water or air can be sequentially removed until the patient is able to expel the balloon. 58 In patients with altered rectal sensitivity, balloon biofeedback can be undertaken by serially inflating a balloon with incrementally smaller or larger volumes; enabling the patient to appreciate rectal filling and to attempt evacuation at an appropriate threshold.
The use of ultrasound imaging can also be used for biofeedback.
Ultrasound can provide real time information about the direction of pelvic floor movement during pelvic floor muscle contraction and relaxation to assist teaching a patient to relax the muscles during defaecation. 59 Head-to-head trials between biofeedback treatment techniques are limited and significant disparity between treatment protocols comparing different techniques makes it challenging to identify the most efficacious procedure (Table 2) . 9 Despite these limitations, Koh et al., undertook a meta-analysis comparing EMG biofeedback with non-EMG biofeedback and found a OR of 6.738 (95% CI, 2.914-15.580, P<.001) favouring EMG. 9 A recent Cochrane Review, while unable to make a clear conclusion of the most efficacious biofeedback modality, also indicated EMG biofeedback demonstrated a slightly superior response compared with balloon biofeedback and manometry, however, the findings were not statistically significant. 60 
| Review criteria and methodology regarding efficacy of biofeedback for dyssynergic defaecation
Online databases searched included Pub Med, MEDLINE Ovid and the Cochrane Central Trials Registry. All original research studies, reviews and systematic reviews published in English from January 1950 onwards were considered. The following key words were used alone or in combination; "constipation and levator ani," "constipation and pelvic floor muscle," "constipation and biofeedback," "dyssynergic defaecation pathophysiology," "dyssynergic defaecation and biofeedback," "pelvic floor muscle and constipation review," "anismus and biofeedback", "obstructive defaecation and biofeedback" and "dyssynergia and biofeedback". Articles were excluded if they 
| Efficacy of biofeedback in dyssynergic defaecation
Biofeedback is practitioner dependent and often individualised to a particular patient's needs. This variability makes intra-and intercentre comparisons challenging and leads to inherent difficulties in designing and interpreting studies. This was recognised in a recent
Cochrane Review which concluded that the efficacy and safety of biofeedback could not be determined due to inadequacies in study methodology and bias. 60 
Nevertheless, despite the limitations highlighted in the Cochrane
Review, the randomised controlled trials in Table 3 but not standard care post-intervention. 61 Heymen et al., compared two control conditions, placebo or diazepam against EMG biofeedback. 64 The trial involved three phases including a run in which involved enhanced standard care including diet, lifestyle measures, stool softeners and scheduled evacuations. Of the 117 patients who commenced the trial, 18 reported adequate relief at the end of run in and were excluded. 64 The remaining 84 patients were randomised to placebo, diazepam and biofeedback. At the 3 month follow-up 70% of the biofeedback group reported adequate relief compared with 30% of the diazepam treated (P<.001) and 38% of placebo Contention also remains as to whether biofeedback improves symptoms in slow transit constipation without dyssynergia. 
| Clinical predictors of success
Biofeedback is a labour intensive therapy predominantly performed in specialised tertiary centers which limits patient access. 71 The majority of biofeedback studies specifically selected patients with a functional defaecation disorder although a smaller number of studies have shown possible benefit in all patients with constipation. Risk factors for a poor response to biofeedback include a long history of constipation, 73 an eating disorder or poor compliance. 68 Manometric findings of inability to evacuate an intrarectal balloon and increased anorectal angle during squeeze have been independently associated with a lack of response to biofeedback. 74 nosing a structural or functional abnormality in these patients (Figure 3) . The scope of this manuscript does not extend to a detailed discussion of these investigations, which have been reviewed in Ahmad et al. 75 
| Botulinum toxin injection
Botulinum toxin injection into nonrelaxing puborectalis has shown variable response in patients with dyssynergic defaecation and is not widely utilised. [76] [77] [78] Based on small uncontrolled studies, Botulinum toxin has demonstrated an inconsistent improvement in symptoms but its effect decreases within 3 months post-injection. In one study, Botulinum toxin injection was found to be superior to biofeedback therapy, however, the success rates of biofeedback in this study were significantly inferior to other published studies. 34, 77 Overall, the recent AGA technical review on constipation has concluded that Botulinum toxin injection, a more invasive therapy, is not superior to biofeedback as first line therapy in patients with dyssynergic defaecation. 
| FURTH ER AREAS OF INTEREST
It has been found that a significant number of patients with inflammatory bowel disease who have evacuatory dysfunction may also have concomitant pelvic floor dyssynergia. 82 Biofeedback therapy in this cohort has demonstrated encouraging results with up to 80% of patients reporting improvement in symptoms. 82 Biofeedback has also been utilised with success in patients with multiple sclerosis, spinal cord and neurogenic bowel dysfunction. 83, 84 In addition, for practical purposes, home biofeedback may enable patients in rural or regional settings to access treatment using an EMG home trainer or silicone probe device and has demonstrated encouraging results. 85 Despite an increase in evidence based research into pelvic floor dyssynergia in chronic constipation and its management, there are a number of areas which require further study. Head-to-head trials of biofeedback modalities need to be undertaken to determine a gold standard therapy. Studies evaluating the economic benefit and impact of biofeedback therapy on reducing primary care visits, medical therapies and expensive testing may allow increased funding for this treatment technique.
| CONCLUSIONS
Dyssynergic defaecation is an under-recognised, potentially reversible cause for chronic constipation. There is no gold standard diagnostic modality for dyssynergic defaecation and further research is required in this area. In patients diagnosed with dyssynergic defaecation, biofeedback therapy is the most efficacious and safe treatment available. Further research into biofeedback therapy with standardised protocols and patient centred outcomes is required to expand its utility in clinical practice.
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